Macular edema (ME) is the most common

Size: px
Start display at page:

Download "Macular edema (ME) is the most common"

Transcription

1 MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause for ME was previously thought to be transudation due to increased venous pressure caused by obstructed outflow, but we now have a greater understanding of the critical role of retinal ischemia leading to release of vascular endothelial growth factor (VEGF). An early pilot study of ranibizumab conducted at the Wilmer Eye Institute in patients with ME due to either branch or central RVOs (BRVO or CRVO) showed a rapid and robust decrease in excess central retinal thickening and a corresponding rapid and robust increase in visual acuity. There was a negative correlation between aqueous VEGF level at baseline and visual outcome, indicating that particularly high VEGF levels were a disadvantage. These results led to pivotal, randomized, controlled trials in patients with BRVO (BRAVO [Efficacy and Safety of Ranibizumab Injection in Patients with ME Secondary to BRVO] study) and CRVO (CRUISE [Efficacy and Safety of Ranibizumab Injection in Patients with ME Secondary to CRVO] study), which have demonstrated impressive benefits over the course of 6 months. Although the long-term effects of ranibizumab are not completely established, continued follow-up for 2 years in patients *Based on a presentation by Dr Campochiaro at a roundtable symposium held in Fort Lauderdale, Florida, on April 30, George and Dolores Eccles Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Address correspondence to: Peter A. Campochiaro, MD, George and Dolores Eccles Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Maumenee 719, Baltimore, MD, pcampo@jhmi.edu. enrolled in the initial pilot trial suggest that as-needed ranibizumab results in complete and partial maintenance of benefits in patients with BRVO or CRVO, respectively. Considering the recent approval of ranibizumab for treatment of RVO by the US Food and Drug Administration, new recommendations for management of RVO are offered. (Adv Stud Ophthalmol. 2010;7(2):42-47) Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). Other causes include retinal hemorrhages, which are reversible, and macular ischemia, which is permanent. ME is initially reversible, but over time, permanent loss of vision occurs from structural damage to the macula. In patients with RVO, veins distal to the obstruction become dilated and tortuous, suggesting increased venous pressure, which has been felt to be the primary reason for leakage of plasma and red blood cells into surrounding retina. Efforts to develop treatments have focused on attempting to eliminate or bypass the obstruction with thrombolytics, surgery, or creation of shunt vessels by inducing arteriovenous anastomoses. However, these concepts have been challenged by new data suggesting that retinal ischemia and release of vascular endothelial growth factor (VEGF) play a critical role. A pilot study conducted at the Wilmer Eye Institute compared 3 monthly injections of 0.3- or 0.5-mg ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA) in patients with ME due to either branch or central RVOs (BRVO or CRVO). With either dose, there was a substantial reduction in excess central retinal thickness within 1 week; by month 3 it was reduced by approximately 90%. This was accom- 42 Vol. 7, No. 2 December 2010

2 Table 1. Primary Results from the BRAVO and CRUISE Studies of Ranibizumab for RVO BRVO CRUISE 0.3-mg 0.5-mg Sham 0.3-mg 0.5-mg Sham ranibizumab ranibizumab ranibizumab ranibizumab Mean change from baseline in BCVA letter score* ( ) ( ) ( ) ( ) ( ) (-2 3.6) Patients who gained > % 61.1% 28.8% 46.2% 47.7% 16.9% letters in BCVA, %* Median percent reduction 97% 97.6% 27.9% 94% 97.3% 23.9% in excess foveal thickness Median reduction in excess foveal thickness, µm* *P <.0001 for each ranibizumab group vs sham, BRAVO, and CRUISE. BCVA = best corrected visual acuity; BRAVO = Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to BRVO; BRVO = branch RVO; CRUISE = Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to CRVO; CRVO = central RVO; RVO = retinal vein occlusion. Data from Campochiaro et al 2 and Brown et al. 3 panied by an average improvement in visual acuity of 15 Early Treatment Diabetic Retinopathy Study letters in all patient groups, a very large effect. Patients with the highest levels of VEGF in the aqueous at baseline tended to have the worst outcomes. 1 These results provided the rationale and assistance in design for 2 pivotal trials, the BRAVO study (Efficacy and Safety of Ranibizumab Injection in Patients with ME Secondary to BRVO; 397 patients with ME following BRVO) and the CRUISE study (Efficacy and Safety of Ranibizumab Injection in Patients with ME Secondary to CRVO; 392 patients with ME following CRVO), comparing monthly intraocular injections of 0.3- or 0.5-mg ranibizumab with sham injections. The results at the 6- month primary end point are shown in Table 1 and mirror those from the pilot study of ranibizumab. 2,3 Although the short-term data with ranibizumab treatment are impressive and compelling, there is less information regarding the long-term effects. The 2- year outcomes are now available for the initial pilot study. After the 3-month primary end point, patients were seen every 2 months and given an injection of ranibizumab if there was recurrent or persistent ME. Five patients with BRVO and 3 with CRVO required 0 or 1 additional injection after the primary end point and had good vision and no edema at the 2-year end point, but the majority of patients required many injections throughout the follow-up period for recurrent edema. As shown in Table 2, with continued asneeded (PRN) ranibizumab injections, most patients Table 2. Level of Improvement After 3 Monthly Ranibizumab Injections, Followed by PRN Injections Over 2 Years, in Patients with BRVO and CRVO BRVO CRVO Level of improvement Month 3 Month 24 Month 3 Month 24 No change (14%) 5 letters 19 (95%) 16 (94%) 18 (90%) 9 (64%) 10 letters 14 (70%) 13 (76%) 14 (70%) 6 (43%) 15 letters 10 (50%) 10 (59%) 11 (55%) 3 (21%) 30 letters 3 (15%) 3 (18%) 0 3 (21%) Reduced 5 letters (10%) 2 (14%) Mean improvement BRVO = branch retinal vein occlusion; CRVO = central retinal vein occlusion; PRN = as needed. Data from Campochiaro et al. 4 Johns Hopkins Advanced Studies in Ophthalmology 43

3 with BRVO were able to maintain the level of vision benefits achieved after 3 monthly injections with an average of 2 injections of ranibizumab during the second year. Mean foveal thickness was also fairly well maintained, but was slightly higher at 2 years compared to 3 months. 4 The situation was somewhat different for patients with CRVO because most but not all of the visual benefits were maintained during the follow-up phase; mean improvement from baseline in visual acuity was 8.5 letters at 2 years compared to 12 letters in the same patients at 3 months (Table 2). 4 The reason for the decline was there was recurrent edema in many patients despite the availability of ranibizumab every 2 months. Such findings suggest that more aggressive follow-up is needed for many patients with CRVO, perhaps visits every month with injections of ranibizumab if needed. Two baseline characteristics were found to predict visual outcome: chronicity of edema and extensive disruption of the perifoveal capillary bed. Patients who had BRVO for 1 year or longer at baseline had no difference in the amount of visual improvement at 2 years compared to patients with shorter duration of disease, but their final vision at 2 years was significantly lower (Table 3). 4 Likewise, patients with BRVO who had disruption of more than 180 of the perifoveal capillary bed were able to achieve substantial improvement in vision, but had a final vision at 2 years that was significantly less than that seen in patients with less than 180 disruption of the perifoveal capillaries. In patients with CRVO, these 2 baseline characteristics had an even greater impact. Patients who had CRVO for more than 1 year at baseline or had extensive disruption of the perifoveal capillaries had significantly less visual improvement and worse final vision at 2 years than patients with CRVO for less than 1 year or patients with minimal disruption of the perifoveal capillaries, respectively. 4 These studies indicate that ranibizumab provides very good benefit in patients with ME due to vein occlusions, out to 2 years, with a good safety profile. However, several questions remain. Can higher doses of ranibizumab provide greater benefit? Can laser to areas of nonperfusion reduce the need for continued injections without sacrificing visual benefit? Should we expect the same results with bevacizumab as ranibizumab? Are they interchangeable? And what is the role of steroids in RVO treatment? TREATMENT RECOMMENDATIONS Ranibizumab has recently been approved for treatment of ME due to BRVO or CRVO. Based on the study results to date, the following treatment regimen is recommended. For patients with ME due to BRVO, treat initially with ranibizumab monthly for 6 months and then observe for approximately 3 months. If recur- Table 3. Factors Affecting Visual Outcome After 3 Monthly Ranibizumab Injections, Followed by PRN Injections Over 2 Years, in Patients with BRVO and CRVO BRVO CRVO N Mean increase in P BCVA at P N Mean increase in P BCVA at P ETDRS letters month 24 ETDRS letters month 24 at month 3 at month 3 RVO 1 y NS RVO >1 y PCD 180º NS PCD >180º PCD = 360º BCVA = best corrected visual acuity; BRVO = branch RVO; CRVO = central RVO; ETDRS = Early Treatment Diabetic Retinopathy Study; NS = not significant; PCD = perifoveal capillary perfusion; PRN = as needed; RVO = retinal vein occlusion. Data from Campochiaro et al Vol. 7, No. 2 December 2010

4 rent ME is observed 3 months after stopping ranibizumab, start PRN treatment with ranibizumab. If frequent injections are needed to control edema during PRN treatment, consider grid laser therapy. If frequent ranibizumab injections are still required 3 months after grid laser, consider steroid therapy (dexamethasone intravitreal implant [Ozurdex; Allergan, Inc, Irvine, CA] or triamcinolone acetonide injectable solution [Kenalog; Bristol-Myers Squibb Company, Princeton, NJ]). For macular edema due to CRVO, the recommendations are similar: monthly injections for 6 months, observation for 2 to 3 months, and then monthly follow-up with PRN ranibizumab injections. If frequent injections are needed to control edema during a PRN treatment phase, one could consider the addition of steroids (dexamethasone intravitreal implant or triamcinolone acetonide injectable solution). We are currently testing whether scatter photocoagulation to areas of nonperfusion can reduce the need for frequent injections of ranibizumab and what effect it has on visual acuity. Patient with BRVO Diana V. Do, MD RH is a 68-year-old man who complains of decreased vision in his left eye for 1 month. His previous medical history includes systemic hypertension. Previous ocular history includes a retinal tear in his left eye, for which he received retinopexy, and glaucoma in the left eye, for which he is receiving topical intraocular pressure-lowering agents. Visual acuity is 20/16 OD, 20/100 OS. Funduscopy of the left eye reveals superotemporal BRVO with intraretinal hemorrhages. Fluorescein angiography was performed in the left eye and demonstrated blockage from the intraretinal hemorrhages. In the late frames of the angiogram, there is some retinal vascular leakage but the hemorrhages obscure much of the leakage. Optical coherence tomography (OCT) of the left eye revealed severe cystoid ME involving the center of the fovea. When would you recommend treatment? If you decide to treat him, what treatment option would you recommend? How long would you follow this patient? For further discussion of the challenges in managing these real-life situations, please go to DISCUSSION DEFINING A PRN REGIMEN Dr Nguyen: Would you recommend a more regular treatment regimen than PRN for CRVO, given that the results you saw were not as good? Dr Campochiaro: This is still a fluid situation as we wait for more long-term data. I think it is reasonable to consider following these patients and treating edema as it recurs because, in general, the recurrences did not leave permanent loss of vision over the short term and therefore you have some flexibility in the way that you approach this. I could not argue vociferously at this point to have a longer period of monthly treatment for patients with CRVO. Dr Kuppermann: What is your PRN approach? What are your criteria for re-treatment? How much edema do you tolerate before you would reinject? Dr Campochiaro: In our long-term trial, for the first year it was ME greater than 250 µm with time domain OCT. In the second year, it was the presence of any intraretinal fluid. That gives you the flexibility to treat, but you do not have to treat. In the patients with BRVO at 2 years, there was on average slightly greater foveal thickness, but the vision was the same. It appears that periodic reduction in edema is enough to salvage the retina from permanent visual loss. Dr Flynn: Are there any data regarding more frequent dosing (eg, every 4 6 weeks) in venous occlusive disease? Dr Campochiaro: In our trial, we chose followup of every 2 months to make the protocol less difficult for patients. The data suggest that this frequency is not ideal for BRVO, but it works pretty well. Their vision is maintained out to 2 years, despite some recurrent edema. For CRVO, every 2 months is probably not sufficient, but there is individual variability so we recommend that you tailor it for individual patients. I think the issue is going to be, after a period of maintenance, whether injections every 6 weeks still work for the patient. The physician could discuss other options to decrease the frequency of visits and reinjections, such as laser and steroids. The approach is likely to evolve. COMPARING RANIBIZUMAB TO BEVACIZUMAB Dr Flynn: Because ranibizumab is not approved for venous occlusive disease, most people are using bevacizumab (Avastin; Genentech, Inc, South San Johns Hopkins Advanced Studies in Ophthalmology 45

5 Francisco, CA) preferentially for that issue. Do you agree with that? Dr Campochiaro: I think that question cannot be answered right now. The results from case studies in which bevacizumab was used are not nearly as good as those from BRAVO and CRUISE or the results that I reported from the long-term follow-up. It is not a completely fair comparison, but some of those cases were treated monthly and the results are just not as good. Anecdotally, clinicians who have used both VEGF antagonists feel that perhaps in diabetic ME and central vein occlusion, there may be advantages to ranibizumab. It is not understood exactly why that would be. It may simply be that the levels of VEGF are higher in those conditions than in neovascular agerelated macular degeneration and BRVO. Dr Do: Although the medical evidence for bevacizumab is level 2 and level 3 for a vein occlusion, there was a recently published prospective study in Europe that included 29 eyes with ME due to vein occlusion, among which the majority had BRVO. The investigators chose a regimen in which they administered 1-mg bevacizumab in 3 scheduled injections, then PRN treatment thereafter. In this small, prospective, nonrandomized study, after 12 months, the mean gain in visual acuity was 16 letters. 5 Although we cannot draw definite conclusions, this study shows that there is good biologic activity with bevacizumab, even though it is off-label use in this condition, too. Until we have a head-to-head comparison, I think it is reasonable to extrapolate and use it in the interim. START WITH LASER OR ANTI-VEGF THERAPY? Dr Davis: Why do you recommend starting with ranibizumab injections rather than starting with grid laser (the current standard of care)? Dr Kuppermann: We should note that, in the BRAVO study, 50% of the sham group received rescue laser, but still did significantly worse than the therapeutic arm. Thus, I do not think we can interpret that as laser being equally efficacious as ranibizumab. Dr Campochiaro: There are some misconceptions about comparing laser to pharmacologic treatments. It is a very difficult comparison because they are such different treatments. There is information coming out that will indicate why it is a good idea to start treatment with ranibizumab early in these conditions. It appears that VEGF becomes part of the driving force of the disease so that patients with CRVO or BRVO start off with capillary nonperfusion from the occlusion. But then over time, their capillary nonperfusion increases. By contrast, in the BRAVO and CRUISE studies, patients who were treated with ranibizumab did not have increased capillary nonperfusion whereas those in the sham group did. This indicates that VEGF causes that increase in nonperfusion, and that by blocking VEGF, the damage can be limited. Also, practically speaking, most of these patients cannot be treated with laser initially because they have hemorrhages throughout their macula. I suggest starting with 6 monthly doses of ranibizumab; some people may want to reduce that to try to decrease the number of injections if retinal hemorrhages are cleared within 3 months and switch to grid laser therapy. But is there a penalty with regard to final visual outcome with grid laser? It has never been studied. The 1-year results with grid laser in the SCORE (Standard Care vs Corticosteroid for RVO) study are much worse than the ranibizumab results. Is it because it takes so much longer for laser that you lose vision because of chronic edema? Or does the grid laser play some role in that loss of vision? Those are unanswered questions. Dr Schmidt-Erfurth: The best parameters for PRN dosing may vary between the different diseases. Vein occlusion is driven mostly by VEGF levels, and VEGF levels correlate with visual acuity and with vision gain, but there are also other cytokines involved. VEGF levels also correlate with OCT thickness, but only early in the disease. During the sham follow-up treatment in BRAVO and CRUISE, the retina flattens even if with sham treatment. That means that there is atrophy of the retina and I think this is the reason why VEGF levels decrease with disease duration in vein occlusion. But it does not mean that visual acuity will become better. Thus I think, early in the disease, it is more VEGF driven but later on, there are other things that add to the mechanism of the vision loss. Dr Kuppermann: Is vein occlusion a biphasal disease is it primarily VEGF-driven initially then an inflammatory disease subsequently in the chronic phase? If so, should we start our treatment with anti- VEGF drugs and then follow up with steroids? Dr Campochiaro: It is an interesting hypothesis that there may be other permeability factors that contribute to ME. There are no good data to really suggest that at this point. If you suppress VEGF, there is a profound effect on ME. 46 Vol. 7, No. 2 December 2010

6 REFERENCES 1. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16: Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion. Sixmonth primary end point results of a phase III study. Ophthalmology. 2010;117: Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology. 2010;117: Campochiaro PA, Hafiz G, Channa R, et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology. 2010;Epub ahead of publication. 5. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93: Johns Hopkins Advanced Studies in Ophthalmology 47

Vascular Disease Ocular Manifestations of Systemic Hypertension

Vascular Disease Ocular Manifestations of Systemic Hypertension Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular

More information

Research Article Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion

Research Article Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion Hindawi Publishing Corporation Journal of Ophthalmology Volume 2016, Article ID 9875741, 6 pages http://dx.doi.org/10.1155/2016/9875741 Research Article Differentiation between Good and Low-Responders

More information

An Update on Branch Retinal Vein Occlusion Treatment Studies. Amiee Ho, O.D. Pacific University College of Optometry

An Update on Branch Retinal Vein Occlusion Treatment Studies. Amiee Ho, O.D. Pacific University College of Optometry An Update on Branch Retinal Vein Occlusion Treatment Studies Amiee Ho, O.D. Pacific University College of Optometry Course Description This course focuses on current treatment options available for macular

More information

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO) Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital

More information

Posterior Segment Macular Edema

Posterior Segment Macular Edema Posterior Segment Macular Edema Treatment of Macular Edema following Branch Retinal Vein Occlusion Raafay Sophie, MD 1 and Peter A Campochiaro, MD 2 1. Post-doctoral Fellow; 2. Eccles Professor of Ophthalmology

More information

FA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences

FA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences FA Conference Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences Patient Presentation CC: (sent by optometrist) Blurry/foggy vision HPI: 62 yo

More information

The Era of anti- - - VEGF Kirk L. Halvorson, OD

The Era of anti- - - VEGF Kirk L. Halvorson, OD The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety

More information

EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO

EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO Yehia Hashad, M.D. Vice President and Global Therapeutic Area Head

More information

Venous Occlusive Diseases

Venous Occlusive Diseases Venous Occlusive Diseases Bruce R. Saran, MD Adjunct Assistant Clinical Professor of Medicine Scheie Eye Institute University of Pennsylvania School of Medicine Philadelphia, PA -a division of: RVO Demographics

More information

Anti VEGF Agents in Retinal Disorders Current Scenario

Anti VEGF Agents in Retinal Disorders Current Scenario Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,

More information

SUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR

SUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,

More information

Retinal vein occlusion (RVO) is a vascular disease

Retinal vein occlusion (RVO) is a vascular disease INTRAVITREAL RANIBIZUMAB FOR RETINAL VEIN OCCLUSION THROUGH 1 YEAR IN CLINICAL PRACTICE TROELS BRYNSKOV, MD,* HENRIK KEMP, MD,* TORBEN L. SØRENSEN, MD, DMSC* Purpose: To evaluate the efficacy and safety

More information

Instudies of vascular endothelial growth factor

Instudies of vascular endothelial growth factor MONITORING THERAPEUTIC EFFICACY IN THE ANTI-VEGF ERA* SriniVas R. Sadda, MD ABSTRACT One of the most important questions with vascular endothelial growth factor (VEGF) inhibitors for age-related macular

More information

Clinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital

Clinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital Clinical Case Presentation on Branch Retinal Vein Occlusion Sarita M. Registered Nurse Whangarei Base Hospital Introduction Case Study Pathogenesis Clinical Features Investigations Treatment Follow-up

More information

Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator

Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator original article Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator Peter A Campochiaro 1, Gulnar Hafiz 1, Syed Mahmood Shah 1, Quan Dong Nguyen

More information

Research Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ The trial: A pilot study to assess the efficacy, durability, and safety of combination ranibizumab + peripheral

More information

Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion

Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(2):108-114 https://doi.org/10.3341/kjo.2017.31.2.108 Original Article Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory

More information

aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer

aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

Comparison of BRVO and CRVO management

Comparison of BRVO and CRVO management Comparison of BRVO and CRVO management Francesco Bandello, MD, FEBO Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele Milan, Italy 1 Financial Disclosure Advisory Board

More information

The Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR

The Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR The Diabetic Retinopathy Clinical Research Network Management of DME in Eyes with PDR 1 What Has Been Learned? Diabetic Retinopathy Treatment Protocol F: Results suggest that clinically meaningful differences

More information

Yoshiro Minami 1*, Taiji Nagaoka 2, Akihiro Ishibazawa 1,2 and Akitoshi Yoshida 2

Yoshiro Minami 1*, Taiji Nagaoka 2, Akihiro Ishibazawa 1,2 and Akitoshi Yoshida 2 Minami et al. BMC Ophthalmology (2017) 17:90 DOI 10.1186/s12886-017-0485-4 RESEARCH ARTICLE Open Access Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema

More information

Applying New Data to Improve the Standard of Care in Retinal Diseases Managing Macular Edema Associated With Retinal Venous Occlusions

Applying New Data to Improve the Standard of Care in Retinal Diseases Managing Macular Edema Associated With Retinal Venous Occlusions Supplement to November/December 2013 CME Activity Applying New Data to Improve the Standard of Care in Retinal Diseases Managing Macular Edema Associated With Retinal Venous Occlusions By Michael Singer,

More information

Supplement to March Ranibizumab: Expanding Horizons in Retinal Vein Occlusion Management. Sponsored by Novartis Pharma AG

Supplement to March Ranibizumab: Expanding Horizons in Retinal Vein Occlusion Management. Sponsored by Novartis Pharma AG Supplement to March 2015 Ranibizumab: Expanding Horizons in Retinal Vein Occlusion Management Sponsored by Novartis Pharma AG Ranibizumab: Expanding Horizons in Retinal Vein Occlusion Management This supplement

More information

Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion

Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion Northern (NHS) Treatment Advisory Group Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion Author: Paul Madill Specialty Registrar in Public Health

More information

From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014

From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 1. This course is designed to review the important ophthalmic literature that was released between October 2013

More information

Diabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel

Diabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel Miss Vasuki Sivagnanavel Consultant Ophthalmologist An update on Diabetic maculopathy Despite advances in the management of diabetes, diabetic retinopathy is already the commonest cause of blindness among

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost

More information

Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham. bars 2014

Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham. bars 2014 Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars 2014 Declaration of interest I have sat on Advisory boards for Novartis and Bayer Involved in Novartis sponsored

More information

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(3):209-216 https://doi.org/10.3341/kjo.2015.0158 Original Article Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with

More information

Applying New Data to Improve the Standard of Care in Retinal Disease. With articles by Gaurav K. Shah, MD Carl D. Regillo, MD.

Applying New Data to Improve the Standard of Care in Retinal Disease. With articles by Gaurav K. Shah, MD Carl D. Regillo, MD. Supplement to July/August 2012 CME Activity Applying New Data to Improve the Standard of Care in Retinal Disease With articles by Gaurav K. Shah, MD Carl D. Regillo, MD Release date: August 2012. Expiration

More information

Treatment of Retinal Vein Occlusion (RVO)

Treatment of Retinal Vein Occlusion (RVO) Manchester Royal Eye Hospital Medical Retina Services Information for Patients Treatment of Retinal Vein Occlusion (RVO) What is a Retinal Vein Occlusion (RVO)? The retina is the light sensitive layer

More information

Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229

Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229 NICE 2018. All

More information

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec

More information

Recalcitrant Diabetic Macular Oedema: Therapeutic Options

Recalcitrant Diabetic Macular Oedema: Therapeutic Options December 2007 A. Giridhar et al. - Recalcitrant DME 451 CONSULTATION S E C T I O N Recalcitrant Diabetic Macular Oedema: Therapeutic Options Dr. Cyrus M Shroff 1, Dr. N S Muralidhar 2, Dr. R Narayanan

More information

Diabetic Macular Edema Treatment in the 21st Century

Diabetic Macular Edema Treatment in the 21st Century Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study

Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study Peter A. Campochiaro, MD, 1 Charles C. Wykoff, MD, 2 David M. Brown, MD, 2 David S. Boyer, MD, 3 Mark Barakat,

More information

RVO RETINAL VEIN OCCLUSION

RVO RETINAL VEIN OCCLUSION RVO RETINAL VEIN OCCLUSION A guide to understanding RVO Take some time to learn about RVO - it may help you hold on to your vision Retinal vein occlusion is a common disorder of the retina and a leading

More information

Retinal Vein Occlusion

Retinal Vein Occlusion Retinal Update 2018 Retinal Vein Occlusion Case Presentations to Myself Branch Vein Occlusion What medical evaluation do you recommend for this 72 year old patient? Is there anything you ask of your medical

More information

TREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY

TREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY TREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY *Michael W. Stewart Professor and Chairman, Mayo School of Medicine, Department of Ophthalmology,

More information

Facts About Diabetic Eye Disease

Facts About Diabetic Eye Disease Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic

More information

Although photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *

Although photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION * PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Evangelos S. Gragoudas, MD ABSTRACT In December 24, the US Food and Drug Administration (FDA) approved pegaptanib sodium. Pegaptanib

More information

Past ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control

Past ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control Past ocular history Patient presents blurred VA DME Case 1 Hemoglobin A1c 11.5% -- patient states sugars have not been in good control PDR with macular edema OU Rishi Singh MD Cleveland Clinic OD OS 1

More information

Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study

Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study David L.J. Epstein, MD, Peep V. Algvere, MD, PhD, Gunvor von Wendt, MD, PhD, Stefan

More information

OCCLUSIVE VASCULAR DISORDERS OF THE RETINA

OCCLUSIVE VASCULAR DISORDERS OF THE RETINA OCCLUSIVE VASCULAR DISORDERS OF THE RETINA Learning outcomes By the end of this lecture the students would be able to Classify occlusive vascular disorders (OVD) of the retina. Correlate the clinical features

More information

Off-label use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions

Off-label use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions Romanian Journal of Ophthalmology, Volume 60, Issue 2, April-June 2016. pp:90-95 GENERAL ARTICLE Off-label use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of

More information

Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta283

Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta283 NICE 2018. All rights

More information

There are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.

There are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD. Subject: Eylea (aflibercept) Original Effective Date: 7/11/2014 Policy Number: MCP-191 Revision Date(s): 10/11/2016 Review Date(s): 12/16/2015; 10/11/2016, 6/22/2017, 7/10/2018 DISCLAIMER This Medical

More information

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant Ophthalmol Ther (2015) 4:51 58 DOI 10.1007/s40123-015-0028-0 CASE REPORT Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant Thomas Bertelmann

More information

ILUVIEN IN DIABETIC MACULAR ODEMA

ILUVIEN IN DIABETIC MACULAR ODEMA 1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for

More information

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Ophthalmic VEGF Inhibitors Page: 1 of 5 Last Review Date: September 20, 2018 Ophthalmic VEGF Inhibitors

More information

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing

More information

measure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control

More information

Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians

Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians 16 % Injection-free after loading phase 65 % Injection-free after loading phase Navilas

More information

Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion

Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion Open Access Original Article Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion Erkan Unsal 1, Kadir Eltutar 2, Pınar Sultan 3, Hulya Gungel

More information

Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion

Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion AOP*** 1 Original Article Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion Rasha I Ali1, Kapil G Kapoor 1,2, Adeel N Khan 1, Syed K Gibran 1 Purpose: To

More information

Clinically Significant Macular Edema (CSME)

Clinically Significant Macular Edema (CSME) Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2

More information

Quantitative Reduction in Central Foveal Thickness After First Anti-VEGF Injection as a Predictor of Final Outcome in BRVO Patients

Quantitative Reduction in Central Foveal Thickness After First Anti-VEGF Injection as a Predictor of Final Outcome in BRVO Patients Original clinical study Quantitative Reduction in Central Foveal Thickness After First Anti-VEGF Injection as a Predictor of Final Outcome in BRVO Patients Rupak Roy, MS, Kumar Saurabh, MS, Avirupa Ghose,

More information

Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion

Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2018;32(1):29-37 https://doi.org/10.3341/kjo.2016.0134 Original Article Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment

More information

Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration

Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration Ophthalmology Volume 12, Article ID 69641, 8 pages doi:1.1155/12/69641 Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular

More information

Treatment practice in the

Treatment practice in the Strategies for managing neovascular AMD and in routine clinical care BY ROD MCNEIL Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema

More information

4/27/2010 INTRODUCTION TO RETINAL VASCULAR DISEASE VENOUS/VENULAR CENTRAL RETINAL VEIN OBSTRUCTION / CRVO ADDITIONAL FEATURES /COMPLICATIONS

4/27/2010 INTRODUCTION TO RETINAL VASCULAR DISEASE VENOUS/VENULAR CENTRAL RETINAL VEIN OBSTRUCTION / CRVO ADDITIONAL FEATURES /COMPLICATIONS INTRODUCTION TO RETINAL VASCULAR DISEASE VENOUS/VENULAR Leo Semes, OD Professor, UAB Optometry 2 CENTRAL RETINAL VEIN OBSTRUCTION CENTRAL RETINAL VEIN OBSTRUCTION / OCCLUSION (CRVO) obstruction of the

More information

The Foundation WHAT IS THE RETINA?

The Foundation WHAT IS THE RETINA? The Foundation American Society of Retina Specialists Committed to improving the quality of life of all people with retinal disease. Branch Retinal Vein Occlusion Retinal vein occlusions occur when there

More information

Diabetic retinopathy (DR) progressively

Diabetic retinopathy (DR) progressively FOCUS ON DIABETIC MACULAR EDEMA * Frederick L. Ferris III, MD ABSTRACT The current state of treatment for diabetic macular edema (DME) is focused on slowing the rate of vision loss through assessment of

More information

Stephen M. Holland 1,2,3, David G. Dodwell 1,2ˆ, Darrel A. Krimmel 1,4 and Christopher M. de Fiebre 5*

Stephen M. Holland 1,2,3, David G. Dodwell 1,2ˆ, Darrel A. Krimmel 1,4 and Christopher M. de Fiebre 5* Holland et al. BMC Ophthalmology (2015) 15:117 DOI 10.1186/s12886-015-0107-y RESEARCH ARTICLE Open Access Retrospective analyses of optical coherence tomography in recurrent macular edema following intravitreal

More information

Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema

Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema Version 6.0 May 21, 2010 Note: See

More information

A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration

A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact Omesh P. Gupta, MD, MBA, Gary Shienbaum, MD, Avni H. Patel, MD, Christopher Fecarotta,

More information

Diabetic Retinopatathy

Diabetic Retinopatathy Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced

More information

Research Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ A 2-year retrospective study of the treatment of retinal vein occlusion with dexamethasone 0.7 mg intravitreal

More information

New Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting

New Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS

ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS ORIGINAL ARTICLE ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS Aggarwal Somesh VP 1, Shah Sonali N 2, Bharwada Rekha M 3,

More information

BMJ Open. For peer review only -

BMJ Open. For peer review only - Comparative efficacy and safety of treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis Journal: Manuscript ID: bmjopen-0-00 Article Type: Research Date Submitted

More information

COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY

COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY Original Article COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY Aggarwal Somesh V 1, Shah Sonali N 2, Bharwada Rekha

More information

Goals/Objectives. Disclosures. Risk Factors RAO and RVO. Risk Factors. Retinal Artery Occlusions Branch and Central

Goals/Objectives. Disclosures. Risk Factors RAO and RVO. Risk Factors. Retinal Artery Occlusions Branch and Central Jeffrey D. Perotti, OD, MS Indiana University School of Optometry Goals/Objectives RETINAL VASCULAR OCCLUSIONS FOR THE PRIMARY CARE CLINICIAN Using cases as a framework, review current evaluation and management

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment

More information

Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches

Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada

More information

RETINAL VEIN OCCLUSIONS (RVO) PREFERRED PRACTICE PATTERNS (PPP) Philippines: 2016

RETINAL VEIN OCCLUSIONS (RVO) PREFERRED PRACTICE PATTERNS (PPP) Philippines: 2016 RETINAL VEIN OCCLUSIONS (RVO) PREFERRED PRACTICE PATTERNS (PPP) Philippines: 2016 The Retinal Vein Occlusions (RVO) Preferred Practice Patterns (PPP) Philippines: 2016 was prepared by the VitreoRetina

More information

New Developments in the treatment of Diabetic Retinopathy

New Developments in the treatment of Diabetic Retinopathy New Developments in the treatment of Diabetic Retinopathy B. Jeroen Klevering University Medical Centre Nijmegen - The Netherlands Topics Management of diabetic retinopathy Interventions a. primary (prevention)

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION RANIBIZUMAB (Lucentis Novartis Pharmaceuticals Canada Inc.) New Indication: Macular Edema Secondary to Retinal Vein Occlusion Recommendation: The Canadian Drug Expert Committee

More information

Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion

Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(2):95-101 https://doi.org/10.3341/kjo.2017.31.2.95 Original Article Natural Short-term Course of Recurrent Macular Edema Following Intravitreal

More information

Ophthalmology Macular Pathways

Ophthalmology Macular Pathways Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological

More information

Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus

Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus Original Paper Received: December 9, 2014 Accepted: February 25, 2015 Published online: June 12, 2015 Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus Alan R. Berger a Alan F. Cruess

More information

Review Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review

Review Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review Hindawi Ophthalmology Volume 2017, Article ID 2407037, 7 pages https://doi.org/10.1155/2017/2407037 Review Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review

More information

Clinical Trials Related to Age Related Macular Degeneration

Clinical Trials Related to Age Related Macular Degeneration Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad

More information

Case Report Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)

Case Report Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex) Case Reports in Ophthalmological Medicine, Article ID 231913, 5 pages http://dx.doi.org/10.1155/2014/231913 Case Report Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone

More information

Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema

Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema Ayman M Khattab MD, FRCS Professor of Ophthalmology Cairo University Diabetic Macular Edema (DME) Diabetic macular

More information

ZEISS AngioPlex OCT Angiography. Clinical Case Reports

ZEISS AngioPlex OCT Angiography. Clinical Case Reports Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Last Review: September 20 Next Review: September 2017 Related Policies 9.03.21 Aqueous Shunts for Glaucoma Intravitreal Corticosteroid Implants Summary An intravitreal implant

More information

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company

More information

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion ORIGINAL RESEARCH Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion Juan Carlos Mesa Gutiérrez Luis Arias Barquet Josep Maria Caminal Mitjana Sergi

More information

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.

More information

ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA

ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA January/February 2015 Supplement to ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA A roundtable discussion with Franck Fajnkuchen, MD, and Paolo Lanzetta, MD Case report by Paolo Lanzetta, MD The answers

More information

Clinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.

Clinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. 1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417

More information

Management of Neovascular AMD

Management of Neovascular AMD Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,

More information

Diabetic Retinopathy A Presentation for the Public

Diabetic Retinopathy A Presentation for the Public Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are

More information

Combination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.

Combination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR. REVIEW ARTICLE Combination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.net Protocol U Cindy Ung 1, Kareem Moussa 1, Yoshihiro Yonekawa

More information

Branch and central retinal vein occlusion

Branch and central retinal vein occlusion Second most common retinal vasclar disorder1 with age (n=3654)2 Estimated worldwide projection: 16 million people affected in at least one eye3 ~520 new cases annally per million poplation3 10-year incidence

More information

Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012

Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012 Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012 Proliferative Diabetic Retinopathy Laser Treatments Medical Treatment Surgical Treatment Diabetic Macular Edema Laser

More information

Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusion. Yi Jiang, MD, and William F. Mieler, MD

Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusion. Yi Jiang, MD, and William F. Mieler, MD REVIEW ARTICLe Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusion Yi Jiang, MD, and William F. Mieler, MD Abstract: The use of anti vascular endothelial growth factor (VEGF)

More information

A retrospective nonrandomized study was conducted at 3

A retrospective nonrandomized study was conducted at 3 Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine 1, Seoul, Korea Hangil Eye Hospital 2, Incheon, Korea Seoul National University Bundang Hospital 3, Seongnam,

More information